Condition: Relapsed/Refractory Multiple Myeloma(MM) · Sponsor: Nanjing Legend Biotech Co.
A prospective, single-arm, open-label dose-exploration and expansion study to evaluate the safety, tolerability, pharmacokinetics, and antitumor efficacy characteristics of LCAR-F33S in patients with relapsed/refractory multiple myeloma(Investigator-initiated Study).
This description comes directly from the study's public registry record.
Tingting Wang · +86 18618260033 · tingting.wang@legendbiotech.cn
Jianling Yao · +86 18610091176 · jianling.yao@legendbiotech.cn
Always discuss trial participation with your own doctor first.
| Beijing Boren Hospital | Beijing, China | Not Yet Recruiting |
| Institute of Hematology & Blood Diseases Hospital | Tianjin, China | Recruiting |
| Institute of Hematology & Blood Diseases Hospital | Tianjin, China | Recruiting |
| Wuhan Union Hospital | Wuhan, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07100067